Proteomics International Laboratories Ltd Total Assets
Proteomics International Laboratories Ltd total assets. Based on the latest financial reports, Proteomics International Laboratories Ltd (PIQ) holds total assets worth AU$11.30 Million AUD (≈ $7.99 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see PIQ stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Proteomics International Laboratories Ltd (2014–2025)
Total assets of Proteomics International Laboratories Ltd from 2014 to 2025. This chart illustrates how Proteomics International Laboratories Ltd's total assets have evolved over time, based on quarterly financial data. See current stock price of Proteomics International Laboratories Lt for real-time trading data and today's change.
Proteomics International Laboratories Ltd - Asset Composition Analysis
Proteomics International Laboratories Ltd Total Assets Breakdown (June 2025)
Proteomics International Laboratories Ltd total assets breakdown as of June 2025. Proteomics International Laboratories Ltd's total assets of AU$11.30 Million consist of 91.5% current assets and 8.5% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$9.42 Million | 74.7% |
| Accounts Receivable | AU$241.07K | 1.6% |
| Inventory | AU$0.00 | 0.0% |
| Property, Plant & Equipment | AU$1.26 Million | 8.5% |
| Intangible Assets | AU$1.01K | 0.0% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Proteomics International Laboratories Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Proteomics International Laboratories Lt working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Proteomics International Laboratories Ltd's current assets represent 91.5% of total assets in 2025, a decrease from 99.7% in 2014.
- Cash Position: Cash and equivalents constituted 74.7% of total assets in 2025, down from 94.7% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is cash and equivalents at 74.7% of total assets.
Proteomics International Laboratories Ltd Competitors by Total Assets
Key competitors of Proteomics International Laboratories Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $752.18 Million |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
Proteomics International Laboratories Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.22 | 4.70 | 10.77 |
| Quick Ratio | 3.22 | 4.70 | 10.77 |
| Cash Ratio | 2.61 | 3.97 | 8.03 |
| Working Capital | AU$5.52 Million | AU$4.44 Million | AU$7.36 Million |
Proteomics International Laboratories Ltd - Advanced Valuation Insights
This section examines the relationship between Proteomics International Laboratories Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.88 |
| Latest Market Cap to Assets Ratio | 0.77 |
| Asset Growth Rate (YoY) | 35.9% |
| Total Assets | AU$14.78 Million |
| Market Capitalization | $11.45 Million USD |
Valuation Analysis
Below Book Valuation: The market values Proteomics International Laboratories Ltd's assets below their book value (0.77x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Proteomics International Laboratories Ltd's assets grew by 35.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Proteomics International Laboratories Ltd (2014–2025)
The table below shows the annual total assets of Proteomics International Laboratories Ltd from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$14.78 Million ≈ $10.46 Million |
+35.92% |
| 2024-06-30 | AU$10.88 Million ≈ $7.69 Million |
+7.94% |
| 2023-06-30 | AU$10.08 Million ≈ $7.13 Million |
+86.72% |
| 2022-06-30 | AU$5.40 Million ≈ $3.82 Million |
-37.25% |
| 2021-06-30 | AU$8.60 Million ≈ $6.08 Million |
+54.82% |
| 2020-06-30 | AU$5.55 Million ≈ $3.93 Million |
+53.41% |
| 2019-06-30 | AU$3.62 Million ≈ $2.56 Million |
-34.10% |
| 2018-06-30 | AU$5.49 Million ≈ $3.89 Million |
+90.18% |
| 2017-06-30 | AU$2.89 Million ≈ $2.04 Million |
+78.06% |
| 2016-06-30 | AU$1.62 Million ≈ $1.15 Million |
-35.92% |
| 2015-06-30 | AU$2.53 Million ≈ $1.79 Million |
-51.62% |
| 2014-06-30 | AU$5.23 Million ≈ $3.70 Million |
-- |
About Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd operates as a medical technology company with a focus on the area of proteomics in Australia, New Zealand, the United States, Europe, India, and Southeast Asia. It provides PromarkerD, a blood test to predict diabetic kidney disease (DKD). The company's products under development include PromarkerEndo, which has completed clinical validation phase for end… Read more